Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population
Author(s)
Ray, Kausik K
Pillas, Demetris
Hadjiphilippou, Savvas
Khunti, Kamlesh
Seshasai, Sreenivasa Rao Kondapally
Type
Journal Article
Abstract
Background
Familial hypercholesterolemia (FH) is common, but underdiagnosed, and few systematic early screening programs exist.
Objective
To assess health outcomes among those with a recorded diagnosis of FH and potential cases of FH with no recorded diagnosis.
Methods
Retrospective cohort study using the UK Clinical Practice Research Datalink. Records of adults were classified as diagnosed FH (FHCoded), or via accepted algorithms using LDL-C and clinical characteristics as potential FH (FHPotential) or unlikely FH (FHUnlikely) using the DLCN or EUROASPIRE criteria (but no record of FH). Outcomes assessed were premature cardiovascular (CV) events, premature deaths and life expectancy.
Results
Among 1,729,046 individuals free from CV events, a record of FHCoded before the age of 40 was 0.3/1000 (IQR 0.3–0.4) and increased with age. Where LDL-C levels were available, 1.8/1000 (IQR 1.6–2.0) could be classified as FHPotential. LDL-C was higher for both FHCoded and FHPotential vs FHUnlikely (185.6 and 216.6 vs 116 mg/dL, respectively, p<0.001). Compared to FHUnlikely both FHCoded and FHPotential cohorts had a higher risk of premature cardiovascular events (both p<0.001) with highest rates among FHCoded. Risk of premature deaths did not differ between FHCoded and FHUnlikely, but was 1.88 (95% CI 1.27–2.78, p = 0.002) for FHPotential vs FHCoded and 2.40 (95% CI 1.57–3.67, p<0.001) for FHPotential vs FHUnlikely. At age 18, the FHPotential cohort had a life expectancy 16 years lower than the FHCoded cohort (p<0.001).
Conclusions
Potential cases of FH had a doubling in risk of premature death and a large reduction in life expectancy compared to individuals with a recorded diagnosis of FH. These findings strengthen the critical importance of identifying potential cases of FH early and early treatment.
Familial hypercholesterolemia (FH) is common, but underdiagnosed, and few systematic early screening programs exist.
Objective
To assess health outcomes among those with a recorded diagnosis of FH and potential cases of FH with no recorded diagnosis.
Methods
Retrospective cohort study using the UK Clinical Practice Research Datalink. Records of adults were classified as diagnosed FH (FHCoded), or via accepted algorithms using LDL-C and clinical characteristics as potential FH (FHPotential) or unlikely FH (FHUnlikely) using the DLCN or EUROASPIRE criteria (but no record of FH). Outcomes assessed were premature cardiovascular (CV) events, premature deaths and life expectancy.
Results
Among 1,729,046 individuals free from CV events, a record of FHCoded before the age of 40 was 0.3/1000 (IQR 0.3–0.4) and increased with age. Where LDL-C levels were available, 1.8/1000 (IQR 1.6–2.0) could be classified as FHPotential. LDL-C was higher for both FHCoded and FHPotential vs FHUnlikely (185.6 and 216.6 vs 116 mg/dL, respectively, p<0.001). Compared to FHUnlikely both FHCoded and FHPotential cohorts had a higher risk of premature cardiovascular events (both p<0.001) with highest rates among FHCoded. Risk of premature deaths did not differ between FHCoded and FHUnlikely, but was 1.88 (95% CI 1.27–2.78, p = 0.002) for FHPotential vs FHCoded and 2.40 (95% CI 1.57–3.67, p<0.001) for FHPotential vs FHUnlikely. At age 18, the FHPotential cohort had a life expectancy 16 years lower than the FHCoded cohort (p<0.001).
Conclusions
Potential cases of FH had a doubling in risk of premature death and a large reduction in life expectancy compared to individuals with a recorded diagnosis of FH. These findings strengthen the critical importance of identifying potential cases of FH early and early treatment.
Date Issued
2023-09
Date Acceptance
2023-08-29
Citation
American Journal of Preventive Cardiology, 2023, 15
ISSN
2666-6677
Publisher
Elsevier
Journal / Book Title
American Journal of Preventive Cardiology
Volume
15
Copyright Statement
© 2023 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001080861600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
Cardiac & Cardiovascular Systems
Cardiovascular disease prevention
Cardiovascular System & Cardiology
DIAGNOSIS
DISEASE
Familial hypercholesterolemia
GUIDANCE
LDL-C
Life Sciences & Biomedicine
MANAGEMENT
PREVALENCE
Science & Technology
Screening
SUBCLINICAL ATHEROSCLEROSIS
Publication Status
Published
Article Number
100580
Date Publish Online
2023-09-06